{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:18:27Z","timestamp":1778260707910,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R21MH118120"],"award-info":[{"award-number":["R21MH118120"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>An increasing number of HIV cure trials involve combining multiple potentially curative interventions. Until now, considerations for designing and implementing complex combination HIV cure trials have not been thoroughly considered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used a purposive method to select key informants for our study. Informants included biomedical HIV cure researchers, regulators, policy makers, bioethicists, and community members. We used in-depth interviews to generate ethical and practical considerations to guide the design and implementation of combination HIV cure research. We analyzed the qualitative data using conventional content analysis focused on inductive reasoning.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We interviewed 11 biomedical researchers, 4 community members, 2 regulators, 1 policy researcher, and 1 bioethicist. Informants generated considerations for designing and implementing combination interventions towards an HIV cure, focused on ethical aspects, as well as considerations to guide trial design, benefit\/risk determinations, regulatory requirements, prioritization and sequencing and timing of interventions, among others. Informants also provided considerations related to combining specific HIV cure research modalities, such as broadly neutralizing antibodies (bNAbs), cell and gene modification products, latency-reversing agents and immune-based interventions. Finally, informants provided suggestions to ensure meaningful therapeutic improvements over standard antiretroviral therapy, overcome challenges of designing combination approaches, and engage communities around combination HIV cure research.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The increasing number of combination HIV cure trials brings with them a host of ethical and practical challenges. We hope our paper will inform meaningful stakeholder dialogue around the use of combinatorial HIV cure research approaches. To protect the public trust in HIV cure research, considerations should be periodically revisited and updated with key stakeholder input as the science continues to advance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-021-00401-8","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T22:54:38Z","timestamp":1634597678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3458-1539","authenticated-orcid":false,"given":"Karine","family":"Dub\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Dee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Sauceda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Gianella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"issue":"8","key":"401_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nri3262","volume":"12","author":"SG Deeks","year":"2012","unstructured":"Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12(8):607\u201314.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"401_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/medethics-2016-103907","volume":"43","author":"KA Freedberg","year":"2017","unstructured":"Freedberg KA, Sax PE. Improving on effective antiretroviral therapy: how good will a cure have to be? J Med Ethics. 2017;43(2):71\u20133.","journal-title":"J Med Ethics"},{"issue":"4","key":"401_CR3","doi-asserted-by":"publisher","first-page":"e1002253","DOI":"10.1371\/journal.pmed.1002253","volume":"14","author":"R Granich","year":"2017","unstructured":"Granich R, Gupta S, Hall I, Aberle-Grasse J, Hader S, Mermin J. Status and methodology of publicly available national HIV care continua and 90\u201390\u201390 targets: a systematic review. PLoS Med. 2017;14(4):e1002253.","journal-title":"PLoS Med"},{"key":"401_CR4","unstructured":"FDA. Backgrounder for FDA\u2019s HIV patient-focused drug development and HIV cure research public meeting; 2013. http:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM354549.pdf. Accessed 23 Sept 2021."},{"key":"401_CR5","unstructured":"TAG. Research toward a cure trials; 2021. http:\/\/www.treatmentactiongroup.org\/cure\/trials. Accessed 23 Sept 2021."},{"issue":"2","key":"401_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/medethics-2015-103115","volume":"43","author":"R Dresser","year":"2017","unstructured":"Dresser R. First-in-human HIV-remission studies: reducing and justifying risk. J Med Ethics. 2017;43(2):78\u201381.","journal-title":"J Med Ethics"},{"issue":"10","key":"401_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.tim.2014.08.003","volume":"22","author":"K Dub\u00e9","year":"2014","unstructured":"Dub\u00e9 K, Henderson GE, Margolis DM. Framing expectations in early HIV cure research. Trends Microbiol. 2014;22(10):547\u20139.","journal-title":"Trends Microbiol"},{"key":"401_CR8","unstructured":"DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents; 2016. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv-guidelines\/31\/adverse-effects-of-arv. Accessed 22 May 2017."},{"issue":"2","key":"401_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1172\/JCI86047","volume":"126","author":"JD Siliciano","year":"2016","unstructured":"Siliciano JD, Siliciano RF. Recent developments in the effort to cure HIV infection: going beyond N = 1. J Clin Invest. 2016;126(2):409\u201314.","journal-title":"J Clin Invest"},{"issue":"10","key":"401_CR10","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2352-3018(15)00186-1","volume":"2","author":"J Ananworanich","year":"2015","unstructured":"Ananworanich J, Barr\u00e9-Sinoussi F. Is it time to abandon single intervention cure trials? Lancet HIV. 2015;2(10):e410\u20131.","journal-title":"Lancet HIV"},{"issue":"6297","key":"401_CR11","doi-asserted-by":"publisher","first-page":"aaf6517","DOI":"10.1126\/science.aaf6517","volume":"353","author":"DM Margolis","year":"2016","unstructured":"Margolis DM, Garcia JV, Hazuda DJ, Haynes BF. Latency reversal and viral clearance to cure HIV-1. Science. 2016;353(6297):aaf6517.","journal-title":"Science"},{"issue":"8","key":"401_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nm.4108","volume":"22","author":"SG Deeks","year":"2016","unstructured":"Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, et al. International AIDS society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016;22(8):839\u201350.","journal-title":"Nat Med"},{"issue":"5","key":"401_CR13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","volume":"158","author":"A Halper-Stromberg","year":"2014","unstructured":"Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014;158(5):989\u201399.","journal-title":"Cell"},{"issue":"1","key":"401_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/imr.12506","volume":"275","author":"DM Margolis","year":"2017","unstructured":"Margolis DM, Koup RA, Ferrari G. HIV antibodies for treatment of HIV infection. Immunol Rev. 2017;275(1):313\u201323.","journal-title":"Immunol Rev"},{"key":"401_CR15","first-page":"1","volume":"2017","author":"RJ Lebbink","year":"2016","unstructured":"Lebbink RJ, De JDCM, Wolters F, Kruse EM, Van HPM, Wiertz EJHJ, et al. A combinational CRISPR\/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Nat Publ Gr. 2016;2017:1\u201310.","journal-title":"Nat Publ Gr"},{"issue":"3","key":"401_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/COH.0b013e32835ef089","volume":"8","author":"DM Margolis","year":"2013","unstructured":"Margolis DM, Hazuda DJ. Combined approaches for HIV cure. Curr Opin HIV AIDS. 2013;8(3):230\u20135.","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"401_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S2055-6640(20)30932-8","volume":"1","author":"Y-C Ho","year":"2015","unstructured":"Ho Y-C, Siliciano JD. Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection. J Virus Erad. 2015;1(4):229.","journal-title":"J Virus Erad"},{"issue":"12","key":"401_CR18","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1002\/eji.201545513","volume":"45","author":"B Autran","year":"2015","unstructured":"Autran B. Toward a cure for HIV: seeking effective therapeutic vaccine strategies. Eur J Immunol. 2015;45(12):3215\u201321.","journal-title":"Eur J Immunol"},{"issue":"188","key":"401_CR19","first-page":"1","volume":"12","author":"R Schwarzer","year":"2019","unstructured":"Schwarzer R, Gramatica A, Greene WC. Reduce and control: a combinatorial strategy for achieving sustained HIV remissions in the absence of antiretroviral therapy. Viruses. 2019;12(188):1\u201331.","journal-title":"Viruses"},{"key":"401_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/aid.2020.0126","volume":"37","author":"JT Kanazawa","year":"2020","unstructured":"Kanazawa JT, Saberi P, Sauceda JA, Dub\u00e9 K. The LAIs are coming! Implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a scoping review. AIDS Res Hum Retroviruses. 2020;37:75\u201388.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"401_CR21","first-page":"39","volume":"73","author":"JL Marcus","year":"2016","unstructured":"Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP, Klein DB, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. JAIDS. 2016;73(1):39\u201346.","journal-title":"JAIDS"},{"key":"401_CR22","first-page":"1","volume":"13","author":"K Dub\u00e9","year":"2017","unstructured":"Dub\u00e9 K, Dee L, Evans D, Sylla L, Taylor J, Brown B, et al. Perceptions of equipoise, risk\u2014benefit ratios, and \u201cotherwise healthy volunteers\u201d in the context of early-phase HIV cure research in the United States: a qualitative inquiry. J Empir Res Hum Res Ethics. 2017;13:1\u201315.","journal-title":"J Empir Res Hum Res Ethics"},{"key":"401_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1089\/aid.2019.0175","volume":"36","author":"K Dub\u00e9","year":"2019","unstructured":"Dub\u00e9 K, Eskaf S, Evans D, Sauceda J, Saberi P, Brown B, et al. The dose response: perceptions of people living with HIV in the United States on alternatives to oral daily antiretroviral therapy. AIDS Res Hum Retroviruses. 2019;36:324\u201348.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"401_CR24","first-page":"273","volume-title":"Research design. Qualitative, quantitative, and mixed methods approaches","author":"J Cresswell","year":"2013","unstructured":"Cresswell J. Research design. Qualitative, quantitative, and mixed methods approaches. 4th ed. Thousand Oaks: Sage Publications; 2013. p. 273.","edition":"4"},{"issue":"3","key":"401_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/COH.0b013e32835ea1c5","volume":"8","author":"B Lo","year":"2013","unstructured":"Lo B, Grady C. Ethical considerations in HIV cure research: points to consider. Curr Opin HIV AIDS. 2013;8(3):243\u20139.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"401_CR26","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/QAD.0000000000000210","volume":"28","author":"JD Tucker","year":"2014","unstructured":"Tucker JD, Rennie S. Social and ethical implications of HIV cure research. AIDS. 2014;28(9):1247\u201350.","journal-title":"AIDS"},{"issue":"5","key":"401_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/COH.0000000000000489","volume":"13","author":"N Eyal","year":"2018","unstructured":"Eyal N, Holtzman LG, Deeks SG. Ethical issues in HIV remission trials. Curr Opin HIV AIDS. 2018;13(5):422\u20137.","journal-title":"Curr Opin HIV AIDS"},{"issue":"12","key":"401_CR28","doi-asserted-by":"publisher","first-page":"e1002470","DOI":"10.1371\/journal.pmed.1002470","volume":"14","author":"K Dub\u00e9","year":"2017","unstructured":"Dub\u00e9 K, Sylla L, Dee L, Taylor J, Evans D, Bruton C, et al. Research on HIV cure: mapping the ethics landscape. PLoS Med. 2017;14(12):e1002470.","journal-title":"PLoS Med"},{"issue":"83","key":"401_CR29","first-page":"1","volume":"22","author":"K Dub\u00e9","year":"2021","unstructured":"Dub\u00e9 K, Kanazawa J, Taylor J, Dee L, Jones N, Roebuck C, et al. Ethics of HIV cure research: an unfinished Agenda. BMC Med Ethics. 2021;22(83):1\u201314.","journal-title":"BMC Med Ethics"},{"key":"401_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-13-173","volume":"13","author":"J Kimmelman","year":"2012","unstructured":"Kimmelman J. A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries. Trials. 2012;13:1\u20138.","journal-title":"Trials"},{"issue":"19","key":"401_CR31","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.2005.04.9296","volume":"24","author":"S Joffe","year":"2006","unstructured":"Joffe S, Miller FG. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol. 2006;24(19):2987\u201390.","journal-title":"J Clin Oncol"},{"issue":"6","key":"401_CR32","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nm0604-570","volume":"10","author":"C Weijer","year":"2004","unstructured":"Weijer C, Miller PB. When are research risks reasonable in relation to anticipated benefits? Nat Med. 2004;10(6):570\u20133.","journal-title":"Nat Med"},{"issue":"19","key":"401_CR33","first-page":"18","volume":"3018","author":"K Dub\u00e9","year":"2019","unstructured":"Dub\u00e9 K, Barr L, Palm D, Brown B, Taylor J. Putting participants at the centre of HIV cure research. Lancet HIV. 2019;3018(19):18\u20139.","journal-title":"Lancet HIV"},{"issue":"1","key":"401_CR34","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2352-3018(20)30234-4","volume":"8","author":"SR Lewin","year":"2021","unstructured":"Lewin SR, Attoye T, Bansbach C, Doehle B, Dube K, Dybul M, et al. Multi-stakeholder consensus on a target product profile for an HIV cure. Lancet HIV. 2021;8(1):e42-50.","journal-title":"Lancet HIV"},{"issue":"1","key":"401_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/medethics-2015-103125","volume":"43","author":"R Brown","year":"2017","unstructured":"Brown R, Evans NG. The social value of candidate HIV cures: actualism versus possibilism. J Med Ethics. 2017;43(1):118\u201323.","journal-title":"J Med Ethics"},{"issue":"22","key":"401_CR36","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1158\/1078-0432.CCR-12-2455","volume":"18","author":"PM LoRusso","year":"2012","unstructured":"LoRusso PM, Canetta R, Wagner JA, Balogh EP, Nass SJ, Boerner SA, et al. Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an institute of medicine workshop. Clin Cancer Res. 2012;18(22):6101\u20139.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"401_CR37","first-page":"S92","volume":"10","author":"W Soo","year":"1995","unstructured":"Soo W, Nauss-Karol C, Elkins M, Barry D. Inter-company collaboration combination trials. Clinical trials subcommittee for the inter-company collaboration for AIDS drug development. J Acquir Immune Defic Syndr. 1995;10(Suppl 2):S92\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"401_CR38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G. How many interviews are enough?: An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"issue":"4","key":"401_CR39","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","volume":"6","author":"B Julg","year":"2019","unstructured":"Julg B, Dee L, Ananworanich J, Barouch D, Bar K, Caskey M, et al. Recommendations for analytical treatment interruptions in HIV research trials. Report of a consensus meeting. Lancet HIV. 2019;6(4):e259\u201368.","journal-title":"Lancet HIV"},{"key":"401_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2055-6640(20)30287-9","volume":"3","author":"SA Garner","year":"2017","unstructured":"Garner SA, Rennie S, Ananworanich J, Dub\u00e9 K, Margolis DM, Sugarman J, et al. Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. J Virus Erad. 2017;3:82\u20134.","journal-title":"J Virus Erad"},{"key":"401_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S2055-6640(20)30009-1","volume":"6","author":"MJ Peluso","year":"2020","unstructured":"Peluso MJ, Dee L, Campbell D, Taylor J, Hoh R, Rutishauser RL, et al. A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. J Virus Erad. 2020;6:34\u20137.","journal-title":"J Virus Erad"},{"key":"401_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/aid.2017.0067","volume":"34","author":"K Dub\u00e9","year":"2017","unstructured":"Dub\u00e9 K, Evans D, Dee L, Sylla L, Taylor J, Weiner BJ, et al. \u201cWe Need to Deploy Them Very Thoughtfully and Carefully\u201d: perceptions of analytical treatment interruptions in HIV cure research in the United States. AIDS Res Hum Retroviruses. 2017;34:67\u201379.","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00401-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-021-00401-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00401-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T23:05:26Z","timestamp":1634598326000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-021-00401-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1186\/s12981-021-00401-8","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"5 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of the University of North Carolina at Chapel Hill approved this empirical research ethics study (study #: 19-0522). All interview participants included in this study provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants provided informed consent to publish de-identified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.G.D. reports grants and\/or personal fees from Gilead Sciences, Merck & Co, and ViiV, consulting fees from AbbVie, and serves on the Scientific Advisory Board of Enochian BioSciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}